217 results
Page 5 of 11
8-K
EX-99.1
lhhilm97 io5xh4
9 Nov 10
Results of Operations and Financial Condition
12:00am
CORRESP
fdf5 a02ts7lrtztb3o
8 Nov 10
Correspondence with SEC
12:00am
8-K
EX-99.1
pgjl0gse7 49f6becvw
21 Oct 10
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer
12:00am
8-K
ec4mzg
21 Oct 10
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer
12:00am
424B5
sos40yasvps btb2
13 Oct 10
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
9sid8 0ssub4nkg
13 Oct 10
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
bba 5wl8hebcrla
4 Aug 10
Discovery Labs Provides Business Update and Reports Second Quarter 2010 Financial Results
12:00am
424B5
4mke1yva pd9lwp
18 Jun 10
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
k0a9yjrpo
17 Jun 10
Discovery Labs Prices $10.0 Million Public Offering of
12:00am
424B5
cmvehad2kwobxj
16 Jun 10
Prospectus supplement for primary offering
12:00am
424B3
jzizb 4lm6ve
15 Jun 10
Prospectus supplement
12:00am
8-K
EX-99.1
uh9nzxv jwqtmhskas
14 Jun 10
Discovery Labs Secures $35 Million Committed Equity Financing Facility
12:00am
8-K
EX-99.1
6yy0iud
9 Jun 10
Discovery Labs Receives FDA Guidance Regarding Preclinical Program to
12:00am
8-K
EX-99.1
yrvvaa39qw6 eqlz
9 Jun 10
Discovery Labs Reports Preliminary Results from Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure
12:00am
8-K
EX-99.1
pyjmr374 t6u5r8six7j
4 Jun 10
Discovery Labs Announces Listing Transfer to NASDAQ Capital Market
12:00am
8-K
EX-99.1
euf 7dqpc4mwlt3ewa
21 May 10
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval
12:00am